News | July 23, 2007

Biotronik Initiates Trial on Complication Rates with Implantable Device Replacement

July 24, 2007 – Biotonik announced that it has enrolled the first patient and largest trial, REPLACE Registry, which focuses on the complications associated with replacements and system upgrades of implantable pacemakers and defibrillators, and is designed to collect important data currently lacking, on risks associated with device generator replacements.
The 1,750 patient registry will utilize FDA approved devices irrespective of the manufacturer. The study represents BIOTRONIK's continued commitment to the medical field of cardiology. Dr. Haffajee indicated that such a registry is long overdue and stated "the actual complication rates, the type of complications, some of which are life threatening, are often unreported and have never been collected in a prospective fashion in an unbiased registry."
"REPLACE is a very important prospective study for physicians who implant these devices. It is well designed to collect important data currently lacking, on risks associated with device generator replacements. With the growing volume of defibrillators implanted for primary prevention purposes the study will provide a better understanding of the risks that can be anticipated for elective generator replacements or system upgrades," said Dr. Jeanne E. Poole, Director of Electrophysiology at University of Washington and National Principal Investigator for the REPLACE Registry.
The REPLACE Registry will be conducted in 75 to 100 centers across the United States, and will be monitored independently by a Clinical Events Committee chaired by Marye Gleva, M.D, Electrophysiologist at Washington University School of Medicine in St. Louis.

For more information: www.biotronik.com

Related Content

ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init